A 67-year-old man presented with generalized muscle pain for 2 months. A potential malignancy was suspected. The patient was subsequently enrolled in the clinical trial of 68Ga-FAPI. Increased activity of FAPI and FDG was observed in muscle lesions. Moreover, 68Ga-FAPI PET/CT showed intense FAPI uptake in the pancreas. Finally, pancreas and left iliopsoas muscle biopsies confirmed the diagnosis of pancreatic cancer with multiple muscle metastases.

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003888DOI Listing

Publication Analysis

Top Keywords

68ga-fapi pet/ct
8
multiple muscle
8
muscle metastases
8
pancreatic cancer
8
muscle
5
pet/ct imaging
4
imaging multiple
4
metastases pancreatic
4
cancer 67-year-old
4
67-year-old man
4

Similar Publications

Background: 68Ga-labled fibroblast activating protein inhibitor (68Ga-FAPI) represents a new and exciting positron emission tomography-computed tomography/magnetic resonance (PET-CT/MR) radiotracer.

Purpose: To compare the diagnostic efficacy of 68Ga-FAPI PET CT/MR and 18F-fluorodeoxyglucose (18F-FDG) PET/CT in metastatic lesions of gynecological cancers (GCs).

Material And Methods: The PubMed, Embase, and Web of Science databases were thoroughly investigated from inception until 22 December 2023.

View Article and Find Full Text PDF

Purpose: The purpose of this study was to evaluate the benefit of dual-time point 68Ga-FAPI-04 PET/CT in staging head and neck squamous cell carcinoma (HNSCC).

Patients And Methods: Sixty-nine treatment-naive patients with HNSCC were enrolled. Each patient underwent whole-body 68Ga-FAPI-04 PET/CT at approximately 30 minutes postinjection and a delayed scan in head and neck region at 2 hours.

View Article and Find Full Text PDF

Gallium-Fibroblast activation protein inhibitor (Ga-FAPI) positron emission tomography/computed tomography (PET/CT) is increasingly used for evaluating various epithelial neoplasms. Despite addressing some pitfalls, many remain unacknowledged. This report details a 77-year-old man with suspected pancreatic malignancy who underwent a Ga-FAPI PET/CT scan post-gastroduodenal coil embolization for upper gastrointestinal bleeding.

View Article and Find Full Text PDF

Semiquantitative muscle parameters derived from FAPI and FDG PET/CT in evaluating sarcopenia among patients with malignant tumors.

Nucl Med Commun

December 2024

PET Center, Department of Nuclear Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University.

Background: The objective of this study is to explore and compare the potential utility of fibroblast activation protein inhibitor (FAPI) and fluorodeoxyglucose PET/computed tomography (CT) in assessing sarcopenia among patients with malignant tumors.

Methods: A retrospective analysis was conducted on 127 patients with histologically confirmed malignant tumors who underwent both 18F/68Ga-FAPI and fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT scans. Clinical characteristics and PET/CT parameters of maximum and mean standard uptake value (SUVmax and SUVmean) of muscle at the 3rd lumbar (L3) level were reviewed.

View Article and Find Full Text PDF

Candida infections have become a growing concern to the immunocompromised patients with cancer. We report a case of liver abscess causing Candida tropicalis candidemia in an immunocompromised patient with pancreatic head cancer on 68Ga-FAPI PET/CT. A 77-year-old man had a history of 10-year duration of uncontrolled diabetes, the presence of neutropenia, immunocompromised condition, and the progression of pancreatic cancer despite the 14 cycles of chemotherapy and palliative radiotherapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!